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 During the past two decades, a number 
of essential and unique functions of 
mitochondria have been discovered that 
are quite distinct from their commonly 
regarded functions as cellular  ‘ power 
stations. ’ 1 Among these, the mitochon-
drial role in cell life / death decisions has 
received special attention. 2 Th e knowl-
edge of such a critical role of mitochon-
dria in cell death is of special signifi cance 
because protecting mitochondria when 
it is needed has become a prosurvival 
cell strategy. While applicable to all 
kinds of cells, it is particularly relevant 
to post-mitotic cells with very low, if any, 
proliferative potential. In particular, the 
role of mitochondria in programmed 
cell death is associated with the release 
of apoptotic signaling molecules (such as 
cytochrome  c , AIF, and SMAC / DIABLO). 
However, the production of reactive 
oxygen species (ROS) by mitochondria 
may also contribute  signifi cantly to any 
cell degradation process. The mecha-
nisms of mitochondrial ROS production 
in cells remain incompletely understood, 
largely because the majority of studies 
revealing ROS production were made in 
model systems. Th is has hampered inter-
pretation of experimental data with 
respect to its application to the behavior 
of mitochondria  in vivo (or at least 
 in situ ). Whatever the mechanisms 
of mitochondrial ROS production, 
researchers have come to a general con-
sensus that mitochondria represent one 
of the major cellular sources of ROS gen-
eration. When these ideas are applied to 
a higher cell organization, a great number 
of tissue pathologies, both inherited and 
acquired, were found to be associated 
with oxidative stress (for example, high 
ROS production); this emphasizes the 
critical role of mitochondria in these 
pathologies. 3 Among acquired tissue 
pathologies, chemically induced toxicity 
aft er pharmacological treatment deserves 
special consideration. 
 Th e use of aminoglycoside antibiotics 
(such as gentamicin) as therapeutic 
agents in the treatment of Gram- negative 
bacterial infections can be signifi cantly 
limited by their nephrotoxicity 4 and 
ototoxicity. Apparently, ROS have 
been shown to play a key role in the 
 toxicity of gentamicin resulting in acute 
kidney injury. 
 Morales  et al. 5 (this issue) report that 
gentamicin-induced kidney injury is 
ameliorated by the widely used insulin-
sensitizing biguanide metformin. Together 
with glibenclamide (an inhibitor of the 
adenosine triphosphate-dependent potas-
sium channel), metformin is considered 
one of only two essential antidiabetic 
medicines by the World Health Organiza-
tion. Th e antihyperglycemic properties of 
metformin are mainly attributed to the 
suppression of hepatic glucose production 
(through suppression of gluconeogenesis) 
and an increase in peripheral tissue insu-
lin sensitivity. Although the exact mode of 
action of metformin has not been fully 
established, there is a set of data pointing 
to the direct or mediated mitochondrial 
eff ect of metformin. On one side, there is 
a claim that when it is used alone, the bene-
fi cial eff ect of metformin may be due to its 
mild inhibition of the mitochondrial res-
piratory chain (apparently of complex I). 6 
Another set of data, including those 
described by Morales  et al. , 5 demonstrates 
that metformin-based combination ther-
apy can eliminate toxic side eff ects. Th is 
beneficial effect of metformin used in 
combination requires some alternative 
explanation. 
 A new look at gentamicin as a mito-
chondrial toxin that can exert its toxic 
eff ects when excreted by the kidney has 
apparently shed light on the complicated 
mechanisms of nephrotoxicity and 
nephroprotection, with mitochondria 
playing a critical role. Pharmacologically 
induced mitochondrial toxicity is oft en 
explained by a direct interference of the 
drug or agent with mitochondrial systems 
such as components of the electron trans-
fer chain, oxidative phosphorylation, the 
transport system of oxidative substrates, 
or the machinery of mitochondrial DNA 
replication. Quite oft en mitochondrial 
toxicity can also be mediated by ROS. 
ROS are normally produced at low levels 
by mitochondria themselves, but under 
pathological conditions the intracellular 
and intramitochondrial ROS content may 
be amplifi ed. 7 Under certain conditions, 
intracellular ROS content can reach a 
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permeabilization, followed by cell death and organ malfunctioning. This 
suggests that a strategy to preserve tissue mitochondria could preserve 
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mitochondria-dependent pathway, normalizing oxidative stress and 
restoring mitochondrial functional integrity. 
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toxic level (this was, in fact, observed aft er 
gentamicin treatment; 5 see  Figure 1 ), 
which results in oxidative damage to ele-
ments essential for proper mitochondrial 
function, causing cell death and malfunc-
tioning of the organ. Th e regulation of 
ROS homeostasis is complicated insofar 
as it involves maintaining a range below 
the threshold of damage but yet able to 
maintain certain key physiological func-
tions of ROS as a redox signal required for 
proper activation of certain enzymes. Th is 
goal can be reached either by regulation 
of ROS production in mitochondria or by 
quenching of the excess ROS by redox 
buff ers (when necessary, introduced into 
the system as exogenously supplemented 
antioxidants). Unfortunately, since the 
exact mechanisms of mitochondrial ROS 
production have not yet been defi ned, the 
regulation of ROS levels in the cell remains 
a diffi  cult problem. 
 Besides ROS, another essential compo-
nent that determines certain forms of cell 
death belongs to the mitochondrial struc-
ture or structures responsible for the so-
called mitochondrial permeability 
transition (MPT), which occurs when the 
mitochondrial inner membrane, nor-
mally impermeable even for protons, 
becomes leaky for compounds up to 
approximately 1.5  kDa (for review, see 
Zorov  et al. 8 ). Morales  et al. 5 have 
revealed a central role of the MPT in 
gentamicin-induced nephrotoxicity. 
Although a complete description of the 
specifi c mitochondrial structure or struc-
tures that can induce this phenomenon is 
lacking, 8 there are a great number of MPT 
inducers, including ROS, that have 
already been described. A few methods 
have become available to observe the 
MPT  in vitro and  in situ . Sensitivity to 
MPT inhibitors (cyclosporine A, 
methylAla(3)ethylVal(4)-cyclosporine 
(Debio 025),  N -methyl-4-isoleucine 
cyclosporine (NIM811), Sanglifehrin A, 
bongkrekic acid, Ca 2  +   chelators, and so 
on) has become a rather powerful meth-
odological approach to reporting the 
involvement of the MPT, 8 and this tool 
has been successfully used in the study by 
Morales  et al. 5 ( Figure 1 ). 
 A very important but frequently 
ignored result of MPT induction is that 
mitochondrial permeabilization causes 
the loss of essential mitochondrial ingre-
dients necessary to perform a major 
mitochondrial function; that is, the 
 process of electron transfer between 
 respiratory complexes, required for 
proper coupling of oxidation with phos-
phorylation and formation of adenosine 
triphosphate, is lost. One important 
ingredient is cytochrome  c , which is 
released from the mitochondrial inter-
membrane space, thus disrupting com-
munication of mitochondrial electron 
transfer complexes III and IV. After its 
release from mitochondria, cytochrome 
 c becomes an important proapoptotic 
 factor. 2 Another factor that mitochon-
dria lose as a result of MPT induction 
is a pool of pyridine nucleotides 
(NAD(P)   +    +  NAD(P)H), essential cofac-
tors of major mitochondrial dehydroge-
nases that provide the mitochondrial 
electron transfer chain with energy via 
electrochemical reducing equivalents. 
This pool is preferentially confined 
within mitochondria, 1,9 and its availa-
bility for donating protons to regu late 
oxidative phosphorylation is rate-limit-
ing in the process of mitochondrial res-
piration. The depletion of this pool 
results in the ceasing of respiration, 
whereas the prevention of NAD(P)   +  
loss by MPT inhibition helps support 
tissue viability. 1,10 Besides being an 
essential cofactor for cytosolic and 
mitochondrial dehydrogenases, pyrid-
ine nucleotides are the source of adeno-
sine diphosphate (ADP)-ribose required 
for a very important signaling reaction, 
namely, ADP-ribosylation. Another 
NAD   +   -consuming system is poly(ADP-
ribose) polymerase, which is activated 
to repair DNA strand breaks accumu-
lated after MPT-mediated apoptotic 
DNA degradation ( Figure 1 ). Th ese data 
point to an extremely important role of 
the MPT in drug cytotoxicity, which is 
exerted through multiple mechanisms 
apparently to ensure cell degradation. 
 Th e strength of the study by Morales 
 et al. 5 is in a fresh look at old data high-
lighting the unwanted targeting of, and 
damage to, mitochondria by some phar-
macological agents. It is quite remarka-
ble that mitochondria, thought to ascend 
from ancient bacteria, are now found to 
be such a target of antibiotics used to 
treat Gram-negative bacterial infections. 
Th e authors have evidently caught what 
is usually missed in research exploring 


















 Figure 1  |  Nephroprotective effect of metformin. Gentamicin (GM) attacks mitochondrial 
targets, causing induction of the mitochondrial permeability transition (MPT) and high 
production of reactive oxygen species (ROS). ROS attack numerous cellular targets, including 
DNA, leading to its breakage. MPT induction results in release of cytochrome  c (Cyt  c ) and 
leakage and depletion of pyridine nucleotides (shown as NADH) due to their consumption 
in the DNA repair process by poly(ADP-ribose) polymerase (PARP). Mitochondrial depletion 
of cytochrome  c and pyridine nucleotides causes mitochondrial respiratory inhibition due to 
inability of the electron transfer chain (ETC) to perform electron transport. Deleterious effects 
of gentamicin are shown by red arrows and objects. Metformin (MF) affords protection against 
gentamicin-induced injury apparently by affecting the primary target, the MPT pore, 
by preventing its opening. The possibility of intramitochondrial transport of metformin is 
shown by the question mark. MIM, mitochondrial inner membrane; MOM, mitochondrial outer 
membrane; TCA, tricarboxylic acid cycle. 
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they demonstrate that aft er gentamicin 
initiates the cell elimination process by 
targeting mitochondria, the result (cell 
death), after the  ‘ point of no return ’ 
(mitochondrial permeabilization 2 ) is 
passed, is reali zed through a number of 
diff erent elements (enhanced ROS pro-
duction, mitochondrial cytochrome  c 
loss, NAD pool depletion) to guarantee 
the outcome. Th e mechanism by which 
metformin interferes with mitochondrial 
permeabilization in this case remains to 
be resolved; this understanding should 
facilitate the development of better 
ways to protect against unwanted cell 
death as a result of (unintended) mito-
chondrial injury. 
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 Glucocorticoids (GCs), introduced 
60 years ago for the treatment of infl am-
matory and autoimmune disorders, 
remain a mainstay of therapy for various 
renal diseases. Indeed, the rate of mortal-
ity from systemic lupus erythematosus fell 
precipitously following the introduction 
of steroids in the early 1950s. Remarkably, 
these agents remain a primary therapy for 
lupus nephritis. Steroids are limited by the 
wide range of untoward eff ects, including 
Cushing ’ s syndrome, dyslipidemia, hyper-
tension, pancreatitis, immunosuppres-
sion, bone necrosis and osteoporosis, 
muscle atrophy, cataracts, and hypogo-
nadism. 1 Consequently, the identifi cation 
of GCs with greater selectivity and spe-
cifi city has been a Holy Grail for many 
pharmacologists. 
 It is disappointing, then, that despite 
extensive eff orts expended in pursuit of 
this goal, very limited progress has been 
made in the development of such agents. 
Th e absence of progress is understand-
able as greater insight has been gained 
in discerning the anti-inflammatory 
mechanisms of action of GCs. One of the 
greatest hurdles in the development of 
more selective anti-infl ammatory agents 
lies in the GC receptor itself. Th e levels of 
the receptor protein are regulated in both 
tissue-specific and cell cycle-specific 
fashions. Additionally, several splice and 
translation variants of the protein have 
been identifi ed. 
 Th ere are three primary mechanisms of 
action of GCs: 2 direct cortisol – GC receptor 
DNA interactions; protein interference 
mechanisms secondary to the transcrip-
tion of gene products that interact with 
the cortisol – GC receptor complex; and 
nongenomic pathways, that is, the interac-
tion of GCs with membrane receptors and 
second messengers. Each of these mecha-
nisms has been well studied in exploring 
the anti-inflammatory mechanisms of 
GCs. Examples of GC-mediated infl am-
matory mechanisms include the inhibi-
tion of prostaglandin production by the 
repression of cyclooxygenase-2; the induc-
tion of MAPK phosphatase I, leading to 
the dephosphorylation and inactivation 
of Jun N-terminal kinase; and the direct 
physical interaction of the cortisol – GC 
receptor complex with nuclear factor-  B. 
Th e last mechanism is particular impor-
tant because nuclear factor-  B induces 
the transcription of cyclooxygenase-2, as 
well as several cytokines, chemokines, and 
cell adhesion molecules. 
 Therefore, there are many levels at 
which the anti-infl ammatory eff ects of 
GCs can be understood, and many sites at 
which GC homologs could be designed to 
increase specifi city and potency. Examples 
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 Understanding the mechanisms of glucocorticoid-mediated inhibition 
of inflammation has been challenging. This is particularly true with 
regard to the development of drugs that mimic the anti-inflammatory 
benefits of steroids while avoiding the untoward metabolic effects. 
F ö rster  et al. report that the inhibition of stress-induced mesangial-cell 
apoptosis by dexamethasone is mediated by sphingosine-1-phosphate. 
These findings identify alternative pathways whereby the 
anti-inflammatory mechanisms of glucocorticoids can be probed. 
 Kidney International (2010)  77, 843 – 845.  doi: 10.1038/ki.2010.72 
 1 Department of Internal Medicine, University of 
Michigan ,  Ann Arbor ,  Michigan ,  USA  
 Correspondence: James A. Shayman, Room 
1560 MSRBII, 1150 West Medical Center Drive, 
Ann Arbor, Michigan 48109 – 0676, USA. 
E-mail:  jshayman@umich.edu 
see original article on page 870
